Evidence map›Paper›PMID 32485418›Full record

SynthesisThrombosis research2020

Thrombosis risk associated with COVID-19 infection. A scoping review.

Fatimah Al-Ani, Samer Chehade, Alejandro Lazo-Langner

Registry-linked trialOpen access · bronzeAbstract readMeta-AnalysisScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Thrombosis research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05967039 (Evaluation of Lung Function, Lung Ultrasound and Functional Capacity in Long-COVID Patients Who Underwent Physical Therapy), which is not on this map. Cited by 225 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 16 pooled it
9.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05967039 unknown statusnot on this mapstarted 2022, after this paper: background citation

Evaluation of Lung Function, Lung Ultrasound and Functional Capacity in Long-COVID Patients Who Underwent Physical Therapy

TypeobservationalSponsorCentro Universitário Augusto MottaRan2022 to 2023Enrolled65ConditionsPost-COVID-19 Syndrome, Long COVIDArmsPhysiotherapy
3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 16 syntheses or guidelines pooled it, 407 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. The Association of Cerebrovascular Disease with Adverse Outcomes in COVID-19 Patients: A Meta-Analysis Based on Adjusted Effect Estimates.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2020
    Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Article

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Fatimah Al-AniDepartment of Medicine, Division of Hematology, Western University, London, ON, Canada.
Samer ChehadeDepartment of Medicine, Division of Hematology, Western University, London, ON, Canada.
Alejandro Lazo-LangnerDepartment of Medicine, Division of Hematology, Western University, London, ON, Canada; Department of Epidemiology and Biostatistics, Western University, London, ON, Canada. Electronic address: alejandro.lazolangner@lhsc.on.ca.
Western University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection by the 2019 novel coronavirus (COVID-19) has been reportedly associated with a high risk of thrombotic complications. So far information is scarce and rapidly emerging.

methodsWe conducted a scoping review using a single engine search for studies assessing thrombosis and coagulopathy in COVID-19 patients. Additional studies were identified by secondary review and alert services.

resultsStudies reported the occurrence of venous thromboembolism and stroke in approximately 20% and 3% of patients, respectively. A higher frequency seems to be present in severely ill patients, in particular those admitted to intensive care units. The thrombotic risk is elevated despite the use of anticoagulant prophylaxis but optimal doses of anticoagulation are not yet defined. Although an increase of biomarkers such as D-dimer has been consistently reported in severely ill COVID-19, the optimal cut-off level and prognostic value are not known. DISCUSSION: A number of pressing issues were identified by this review, including defining the true incidence of VTE in COVID patients, developing algorithms to identify those susceptible to develop thrombotic complications and severe disease, determining the role of biomarkers and/or scoring systems to stratify patients' risk, designing adequate and feasible diagnostic protocols for PE, establishing the optimal thromboprophylaxis strategy, and developing uniform diagnostic and reporting criteria.

Indexed as

Blood CoagulationAnticoagulantsAntiviral AgentsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentHost-Pathogen InteractionsHumansPandemicsPneumonia, ViralRisk AssessmentRisk FactorsSARS-CoV-2Treatment OutcomeVenous ThrombosisAnticoagulantsAntiviral AgentsAnticoagulationCOVID-19Venous thromboembolism

Identifiers

PMID32485418
PMCPMC7255332
OpenAlexW3032541896

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.